MedicaidPrior AuthMedium impact
MAB2022110403
Pennsylvania Medicaid (DHS)·PA · Cardiology, Family Medicine, Internal Medicine +1 more·Provider Bulletin
Effective date
Jan 9, 2023
We identified it
Jun 20, 2026
Summary
Pennsylvania Medical Assistance program has removed the prior authorization requirement for Ranexa (ranolazine) from the Antianginal Agents class, effective January 9, 2023. Prior authorization will still be required for other non-preferred antianginal agents and quantities exceeding limits.
Action Required
By January 9, 2023: Billing team must update prior authorization requirements to remove Ranexa (ranolazine) from drugs requiring pre-approval for Pennsylvania Medicaid patients. Update billing system and staff training materials to reflect that Ranexa no longer needs prior auth while other non-preferred antianginal agents still do. Verify current preferred drug list for other antianginal medications.